Julie Hallet, MD, MSc, FRCSC, Assistant Professor at the University of Toronto, Susan Leslie Clinic for Neuroendocrine Tumours speaks about JNCCN Study Reveals Neuroendocrine Tumor Mortality Patterns to Inform Treatment Decisions.
According to recent research published in the August 2021 edition of JNCCN—Journal of the National Comprehensive Cancer Network, the risk of dying of cancer was higher than the chance of dying of other causes in all patients with neuroendocrine tumors (NETs), although mortality varied by primary tumor location. It’s the first population-based cohort research to look at the variables linked to cancer-specific mortality following a NET diagnosis.
Individuals with bronchopulmonary and pancreatic NETs had the highest risk of cancer-specific death, according to a retrospective analysis of 8,607 patients whose health data was held at ICES, a not-for-profit research organization in Toronto, Canada. Non-cancer fatalities outnumbered cancer-specific deaths in the non-metastatic stomach, small intestine, colonic, and rectal NETs. According to the researchers, increasing age, increased material deprivation, and metastases were linked to larger hazard ratios of cancer-specific mortality, but being female and having a higher comorbidity load were linked to a higher proportion of cancer-unrelated death.
Researchers also noted that looking at factors linked to cancer-specific and non-cancer-related death revealed that efforts to combat cancer-specific death in NETs “should include special considerations for older adults and socioeconomically disadvantaged patients to ensure they can access and receive care throughout their cancer journey.”
The research was published in the August edition of JNCCN. The journal also announced a new impact factor of 11.908 for the previous year in this issue. Since 2017, when it was 6.471, the number has gradually increased. The yearly average number of citations of papers published in the journal during the preceding two years is reflected in the impact factor of an academic journal, which is a scientometric index developed by Clarivate. JNCCN is currently ranked 23rd out of 331 oncology journals by impact factor, putting it in the top 7%.
Visit JNCCN.org to read the whole research. Until November 10, 2021, you may get free access to “Risk of Cancer-Specific Death for Patients Diagnosed with Neuroendocrine Tumors: A Population-Based Analysis.”